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Objective: Platelets express the a2b1 integrin and the glycoprotein VI (GPVI)/FcRc
complex, both collagen receptors. Understanding platelet-collagen receptor
function has been enhanced through use of genetically modified mouse models.
Previous studies of GPVI/FcRc-mediated collagen-induced platelet activation were
perfomed with mice in which the FcRc subunit was genetically deleted (FcRc2/2) or
the complex was depleted. The development of a2b12/2 and GPVI2/2 mice permits
side-by-side comparison to address contributions of these collagen receptors in
vivo and in vitro.
Approach and Results: To understand the different roles played by the a2b1
integrin, the GPVI receptor or FcRc subunit in collagen-stimulated hemostasis and
thrombosis, we compared a2b12/2, FcRc2/2, and GPVI2/2 mice in models of
endothelial injury and intravascular thrombosis in vivo and their platelets in
collagen-stimulated activation in vitro. We demonstrate that both the a2b1 integrin
and the GPVI receptor, but not the FcRc subunit influence carotid artery occlusion
in vivo. In contrast, the GPVI receptor and the FcRc chain, but not the a2b1 integrin,
play similar roles in intravascular thrombosis in response to soluble Type I collagen.
FcRc2/2 platelets showed less attenuation of tyrosine phosphorylation of several
proteins including RhoGDI when compared to GPVI2/2 and wild type platelets. The
difference between FcRc2/2 and GPVI2/2 platelet phosphotyrosine levels
correlated with the in vivo thrombosis findings.
Conclusion: Our data demonstrate that genetic deletion of GPVI receptor, FcRc
chain, or the a2b1 integrin changes the thrombotic potentials of these platelets to
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collagen dependent on the stimulus mechanism. The data suggest that the FcRc
chain may provide a dominant negative effect through modulating signaling
pathways in platelets involving several tyrosine phosphorylated proteins such as
RhoGDI. In addition, these findings suggest a more complex signaling network
downstream of the platelet collagen receptors than previously appreciated.

Introduction
Hemostasis relies on the highly regulated balance of prothrombotic and
antithrombotic components to prevent blood loss from the vasculature while at
the same time maintaining blood fluidity. Platelets play a central role in this
balance especially during arterial hemostasis and pathological thrombosis.
Fibrillar collagens represent a potent prothrombotic stimulus for platelets at sites
of vascular injury.
Platelets express two receptors, a2b1 integrin and the glycoprotein VI (GPVI)/
Fc receptor-gamma (FcRc) complex, that together mediate platelet adhesion and
activation in response to collagens (1–3). The a2b1 integrin, a heterodimeric
transmembrane receptor, provides strong adhesion. GPVI, a single span
transmembrane receptor with two immunoglobulin domains non-covalently
associates with the FcRc chain that contains the immunoreceptor tyrosine-based
activation motif (ITAM), which in complex form the primary collagen signaling
receptor (4–6).
A role for a2b1 integrin-mediated adhesion in vascular disease was suggested by
epidemiologic studies that linked a2b1 integrin density to pathologic thrombosis
and enhanced bleeding. Kunicki et al. demonstrated that a2b1 integrin density on
the platelet surface directly correlates with platelet adhesiveness to Type I collagen
(7). We previously reported that the a2b1 integrin-deficient (a2b12/2) mice
clearly exhibit impaired adhesion to collagen substrates under arterial flow
conditions and observed a marked decrement in thrombus formation in vivo
following arterial injury (8).
Similarly, the importance of the GPVI/FcRc complex in normal hemostasis was
demonstrated in patients with a mild bleeding diathesis associated with either
mutations in the Gp6 gene or presence of anti-GPVI antibodies (1,9–11). Collagen
or collagen-related peptides (CRPs) binding to the GPVI subunits stimulate
clustering of the GPVI/FcRc complex, tyrosine phosphorylation of the ITAM
motifs within FcRc chains, and activation of the Src family tyrosine kinases Fyn
and Lyn that trigger platelet activation (12,13). Phosphorylation of the ITAM
domain also results in activation of Syk and downstream effectors, including
PLCc2, PI3K, and small GTPases that contribute to platelet activation and
aggregation (13). Earlier studies of GPVI/FcRc-mediated collagen-induced
platelet activation and thrombus formation were carried out using mice in which
either the FcRc subunit was genetically deleted [FcRc-deficient (FcRc2/2) mice]
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or the complex was depleted by antibody-mediated internalization. Of note,
platelets derived from FcRc2/2 mice fail to express GPVI. In these studies, lack of
FcRc through genetic knockout or antibody-depletion resulted in attenuated
collagen-stimulated platelet activation and thrombus formation under flow
conditions in vitro, however the phenotype in vivo still remains unclear (14–18).
Importantly, the FcRc2/2 animals also lack FceRcI, FccRIII, and FccRI, and are
immunodeficient with abnormalities in macrophage, NK cell, mast cell and B cell
function. More recently, GPVI-deficient (GPVI2/2) mice were developed. These
mice were reported to be viable and fertile, and to exhibit normal bleeding times.
However, GPVI2/2 platelets did not aggregate in response to collagen or GPVIspecific collagen related peptide (CRP) (15). Although GPVI-null platelets did not
form aggregates when perfused over a collagen surface, they did form an adherent
monolayer. Kato et al. attributed the residual adhesion solely to von Willebrand
factor (15). Conversely, other groups showed decreased platelet adhesion to
collagen upon loss of GPVI (14,18,19). These discrepancies suggest that much
remains to be understood about the mechanisms of collagen receptor signaling in
platelets.
The development of a2b12/2, FcRc2/2, and GPVI2/2 mice allowed us to
compare the roles and contributions of these platelet collagen receptors in sideby-side comparisons in vivo and in vitro (15,20,21). Here we report data
comparing GPVI2/2, FcRc2/2, and a2b12/2 mice using in vivo and in vitro assays
of thrombosis. Unexpectedly, the GPVI2/2 and FcRc2/2 mice demonstrated
different defects, suggesting distinct phenotypes of platelets lacking GPVI or FcRc.
These data show that the platelet responses to collagen in FcRc2/2 mice differ
from GPVI2/2 mice and raises caution to utilizing these two knockout mice as
similar systems.

Materials and Methods
Materials
Collagen I from rat-tail tendon was purchased from Upstate Cell Signaling
Solutions. Bovine serum albumin (BSA), DMSO, glutarahldehyde, EDTA, MgCl2,
PGE1, p-nitrophenol-N-acetyl-b-D-glucosaminide, Apyrase, and other chemicals
were purchased from Sigma Aldrich. Anti-phosphotyrosine (p-Tyr-100), antiphospho-Syk (Tyr 525/526), and anti-RhoGDI (#2564) monoclonal antibodies
were purchased from Cell Signaling Technology. Anti-actin polyclonal antibody
(C11) was purchased from Santa Cruz Biotechnology. Goat anti-mouse and
mouse anti-goat secondary antibodies conjugated to horseradish peroxidase and
West-femto chemiluminescence substrate were purchased from Pierce. Hank’s
Balanced Salt Solution lacking divalent cations (HBSS-) was purchased from
Invitrogen.
The a2b12/2 mice, backcrossed onto the C57BL/6 background were previously
reported (20). FcRc-deficient mice on the C57BL/6 and C57BL/6 X 129/SvJ
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background were purchased from Jackson Labs. GPVI-deficient mice on a C57BL/
6 X 129/SvJ background were developed by Kato et al. (15). GPVI-deficient mice
were backcrossed 8 times to the C57BL/6 background using a microsatellite
marker-assisted selection (‘‘speed congenics’’), as previously described (20).
Animals were housed in pathogen-free conditions at Vanderbilt University
Medical Center in compliance with IACUC regulations. The protocol was
approved by the Internal Review Board at Vanderbilt University (protocol #M/
05/324). All animals were appropriately age and sex matched, and efforts were
made to minimize suffering.

Platelet isolation
Murine PRP or washed platelets were prepared from blood obtained on the day of
the experiment according to protocols described previously (22).

Platelet adhesion assay
Adhesion assays were carried out using washed platelets (16108 platelets/mL) as
done previously (22). Measurements for each data point were performed in
triplicate.

Platelet aggregation
Aggregation assays using PRP were performed on a BIO/DATA Corporation PAP4 aggregometer at 37 ˚C with stirring (1200 rpm) as described (20). Agonists were
added at designated final concentrations.

In vivo photochemical injury of the carotid artery of mice
Carotid artery thrombosis was induced as described previously (8). Briefly, male
mice approximately 12 weeks of age were anesthetized with an intraperitoneal
injection of sodium pentobarbital, secured in the supine position, and placed
under a dissecting microscope. The right common carotid artery was isolated
through a midline cervical incision, and an ultrasonic flow probe (Model 0.5 VB;
Transonic Systems) was applied. A 1.5-mW, 540-nm laser beam (Melles Griot)
was applied to the artery from a distance of 6 cm. Rose-Bengal dye (Fisher
Scientific), 50 mg/kg body weight, was then injected into the tail vein, and flow in
the vessel was monitored until complete occlusion occurred.

In vivo collagen-induced pulmonary thromboembolism in mice
Collagen-induced thrombosis was carried out as previously described (8). Briefly,
female mice were anesthetized by intraperitoneal injection of 100 to 150 mL of a
mixture of ketamine and xylazine. Blood was collected into EDTA-coated
microtainer tubes for determination of the baseline platelet count and hematocrit.
25 mg of collagen (equine tendon Type I fibrillar collagen) along with 1 mg
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epinephrine (Sigma) in phosphate-buffered saline (PBS), or PBS alone, were
injected into the right jugular vein; 1 minute after injection a second blood sample
was taken and cell counts were measured. Mice were humanely sacrificed 3
minutes after injection and lungs were collected and placed in formalin.
Pulmonary thrombi were quantitated using digital imaging of lung sections
stained with hematoxylin and eosin using an Olympus Camedia C-3040 Zoom
camera. Five random 20X fields were photographed for each specimen. Analysis of
thrombus number for each mouse lung was made using Olympus Camedia
Master 2.5 software, and then expressed as thrombi per square millimeter¡SEM.

Scanning electron microscopy
Platelet adhesion assays similar to those described above were performed with
minor changes. Platelets at a concentration of 26107 platelets/mL were allowed to
adhere to substrates (30 mg/mL) bound to round glass coverslips (Electron
Microscopy Sciences; 22 mm diameter) for 1 hour at 37 ˚C. Coverslips were
washed 3 times with adhesion buffer. Adherent platelets were fixed using 2%
glutaraldehyde for 30 minutes at 21 ˚C, washed 3 times with 0.1 M sodium
cacodylate buffer and processed (fixed, dried, and sputter coated) in the VUMC
Cell Imaging Shared Resource and the EM Core. Imaging was done using a
Hitachi S-4200 Scanning Electron Microscope.

Mouse platelet phosphotyrosine analysis
Mouse platelets were resuspended at a concentration of 56108 platelets/mL in
HBSS- containing 2 mM MgCl2. Mouse platelets (wild type, GPVI2/2, or FcRc2/2)
were either untreated or stimulated with 10 mg/mL collagen Type I for 1 minute
at 21 ˚C after which an excess of ice-cold HBSS- was added to stop the interaction.
Platelets were pelleted at 4,000 rpm for 4 minutes at 4 ˚C. Platelets were lysed using
SDS-PAGE sample buffer containing protease and phosphatase inhibitors and run
on a reducing 10% SDS-PAGE gel. The proteins were transferred to a nitrocellulose
membrane followed by immunoblot analysis with anti-phosphotyrosine (12000) or
anti-actin (12000) antibodies. Appropriate secondary antibodies linked with
horseradish peroxidase were used with a chemiluminescence substrate to image
the labeled protein bands using a BioRad ChemiDoc with Quantity One software.
Densitometry on protein bands of interest from image files was done using ImageJ
software.

Statistical analyses
The data from multiple different animals were analyzed by Fisher’s least
significant difference approach. Means, standard deviations (SD), standard error
of the means (SEM), t-test, one-way, and two-way ANOVA for column statistics,
and nonlinear curve fits were calculated using GraphPad Prism 4 software.

PLOS ONE | DOI:10.1371/journal.pone.0114035 November 21, 2014

5 / 20

a2b1 Integrin and GPVI/FcRc Receptor in Mouse Models of Thrombosis

Results
Deletion of the GPVI and FcRc receptors, but not the a2b1 integrin
alters collagen-induced intravascular thrombosis and pulmonary
embolism
Distinct biological roles for the a2b1 integrin and the GPVI-FcRc receptor in
platelet activation and thrombus formation in vitro have been well described. To
further understand the complex roles played in vivo by the a2b1 integrin and the
GPVI/FcRc complex, mice with targeted deletion of the distinct receptors were
evaluated using models of collagen-induced thrombosis. Intravenous injection of
collagen Type I into wild type animals resulted in rapid onset of intravascular
thrombosis, a profound decrease in the number of circulating platelets, massive
pulmonary emboli, and death (as previously reported and Figure 1A and B).
Pulmonary thrombosis occurred rapidly, therefore the experiment was completed
in 3 minutes. It was difficult to evaluate time-dependent differences in this model
in which collagen-induced platelet activation is independent of shear stress.
Since the GPVI2/2 mice were generated on a mixed 129/SvJ/C57BL/6
background, as previously reported, we first studied the GPVI2/2, a2b12/2,
FcRc2/2 and littermate control wild type mice on the mixed genetic background.
Baseline platelet counts of a2b12/2, GPVI2/2, and FcRc2/2 mice were similar to
the wild type controls (data not shown). Age-matched animals of all four
genotypes were injected with soluble collagen and platelet counts were evaluated
after 1 minute. A percentage decrease in platelet count was quantitated using the
platelet count before, compared to 1 minute after collagen injection. The platelet
count in wild type (n513) and a2b12/2 mice (n517) decreased by 79.4%¡6%
and 77.6%¡8.2%, respectively. These values were not significantly different and
agreed with previously reported data (8). In contrast, the platelet count in FcRc2/2
and GPVI2/2 mice decreased by 38%¡5% (n57) and 11%¡1% (n57),
respectively (Figure 1A). Platelet count decrement was therefore significantly less in
both the FcRc2/2 and GPVI2/2 mice when compared to wild type (P,0.0001 for
both) or a2b12/2 mice (P,0.0001 for both). Surprisingly, the platelet count
decrease in GPVI2/2 animals was also significantly less than the platelet count
decrease in FcRc2/2 mice (P50.008), suggesting a difference in collagen-induced
thrombosis between mice lacking the GPVI receptor and the FcRc chain
(Figure 1A).
Quantitative analysis of pulmonary thrombi revealed a large number of
intravascular thrombi in wild type and a2b12/2 mice [28¡5 thrombi/mm2
(n513) and 29¡7 thrombi/mm2 (n517) (P.0.5)], respectively (Figure 1B). The
number of thrombi formed in FcRc2/2 mice [8¡2 thrombi/mm2 (n58)] or
GPVI2/2 mice [1.5¡0.2 thrombi/mm2 (n58)] was significantly reduced when
compared to wild type or a2b12/2 mice (P,0.0001 for each analysis)
(Figure 1B). Although the FcRc2/2 mice developed significantly fewer thrombi
than either the wild type or the a2b12/2 mice, the number of thrombi in the
lungs of FcRc2/2 mice was significantly greater than in the GPVI2/2 mice
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Figure 1. Deletion of the GPVI and FcRc receptors, but not the a2b1 integrin alters collagen-induced
intravascular thrombosis and pulmonary embolism. (A) The percentage decrease in platelet count 3
minutes after injection of Type I collagen (25ug) and epinephrine (1ug) was determined for wild type (WT),
a2b12/2, GPVI2/2, FcRc2/2, a2b12/2/GPVI2/2, and a2b12/2/FcRc2/2 mice on the mixed genetic
background (129/SvJ 6 C57BL/6). (B) The number of pulmonary thrombi after injection of Type I collagen
was determined for wild type (WT), a2b12/2, GPVI2/2, FcRc2/2, a2b12/2/GPVI2/2, and a2b12/2/FcRc2/2
mice on a 129/SvJ 6 C57BL/6 background. Thrombi were recorded per mm2 in 6 random 20X fields.
doi:10.1371/journal.pone.0114035.g001

(P,0.0001). These data further support the difference between GPVI2/2 and
FcRc2/2 mice in thrombotic response to collagen.

In the absence of FcRc receptor, the a2b1 integrin contributes to
intravascular thrombus formation
To define the overlapping and/or synergistic roles of the platelet collagen
receptors in vivo, we compared platelet decrement and pulmonary thrombi in
mice with combined deficiency of the GPVI or FcRc receptor and the a2b1
integrin on a mixed SvJ129/C57BL/6 background. The platelet count decrement in
the a2b12/2/FcRc2/2 animals was 20%¡3% (n58), significantly less than the
platelet decrement in wild type or a2b12/2 mice (P,0.0001 for both analyses),
but surprisingly also significantly less than the decrement in the FcRc2/2 mice
(P50.02) (Figure 1A). In the a2b12/2/GPVI2/2 mice (n510), the platelet count
decreased by 12%¡2% (n510) (Figure 1A), therefore, significantly less than wild
type mice or a2b12/2 mice (P,0.0001 for both) and significantly less than
a2b12/2/FcRc2/2 (P50.02) but not different from mice lacking the GPVI
receptor alone (P50.99). The lack of a difference in mice lacking both GPVI and
a2b1 integrin may be due to the very low level of platelet aggregation and further
changes could not be detected. However, loss of a2b1 did attenuate thrombosis
when paired with loss of FcRc chain.
Thrombus formation in the lungs was evaluated in all genotypes (Figure 1B).
The number of thrombi identified in the lungs of a2b12/2/FcRc2/2 animals was
2¡1 thrombi/mm2 (n58) and statistically decreased when compared to the
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number of thrombi in the lungs of wild type, a2b12/2 (P,0.0001 for both), or
FcRc2/2 mice (P50.007). a2b12/2/FcRc2/2 animals developed more thrombi
than GPVI2/2 mice (P50.007). Only rare thrombi were identified in the lungs of
either a2b12/2/GPVI2/2 animals [1¡0.2 (n510)] or GPVI2/2 mice [1.5¡0.2
(n58)]. These data suggest that in the absence of the FcRc, the a2b1 integrin
plays a significant role in the intravascular thrombi development. In the absence
of the GPVI receptor, the response to collagen is so low that an additional
contribution by the a2b1 integrin could not be defined.

Deletion of either the a2b1 integrin or the GPVI subunit, but not the
FcRc receptor delays carotid artery thrombosis
We analyzed platelet activation in a second in vivo model of thrombosis that
involves photochemical damage of the artery to produce endothelial cell
denudation and subendothelial extracellular matrix exposure under shear stress
conditions (23). This assay uses laser-activated Rose-Bengal dye to produce the
photochemical injury of the mouse carotid artery in order to measure the time to
complete vessel occlusion (Figure 2). We compared the time required for
complete arterial occlusion in a2b12/2, FcRc2/2, GPVI2/2 and wild type mice.
As previously reported, the time to complete occlusion was significantly
prolonged in the a2b12/2 animals (74.5¡19.8 minutes) compared to wild type
littermates (44.4¡7.8 minutes) (P50.0002) and to animals lacking FcRc
(P50.008). Occlusion times for FcRc2/2 mice (39.3¡15.9 minutes) were not
different from wild type mice (P50.99). In contrast, occlusion times for the
GPVI2/2 mice (74.6¡28.3 minutes) were statistically increased compared to
those in wild type (P50.0002) and FcRc2/2 mice (P50.004), but similar to
a2b12/2 mice (P50.3). In this second in vivo model of platelet function, the time
to complete arterial occlusion was different in the FcRc2/2 and GPVI2/2 mice.

The in vivo thrombotic differences are independent of genetic
background
Since the differences observed between the GPVI2/2 and FcRc2/2 mice were
unexpected and platelet responses are known to be dependent in some
circumstances on genetic background, we acquired or generated animals on a pure
C57BL/6 background, as described in Methods. Studies of platelet response to
collagen were repeated and platelet count decrements in mice on a pure C57BL/6
background were determined. The results obtained for platelet count decrement
and number of pulmonary thrombi following intravenous injection of collagen
into wild type, GPVI2/2, FcRc2/2 or a2b12/2 pure C57BL/6 animals were similar
to that observed on the mixed background (Figure 3A and 3B). As observed in
mice on a mixed background, there was no difference in platelet count decrement
or in the number of thrombi between wild type (n57) and a2b12/2 animals
(n511) (P50.4), but a significant difference was seen between wild type animals
and FcRc2/2 (n59) (P50.0001) or GPVI2/2 mice (n57) (P50.0001). In
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Figure 2. Deletion of either the a2b1 integrin or the GPVI subunit, but not the FcRc receptor delays
carotid artery thrombosis. The length of time to complete arterial occlusion following photochemical injury of
the carotid artery was recorded in wild type (WT), a2b12/2, FcRc2/2, and GPVI2/2 mice on a mixed genetic
background (129/SvJ 6 C57BL/6). The values represent the mean ¡ SD for WT (n512), a2b12/2 (n515),
GPVI2/2 (n57), or FcRc2/2 (n57) animals.
doi:10.1371/journal.pone.0114035.g002

addition, as observed on the mixed background, there was a significant difference
in platelet decrement (P50.0001) and the number of thrombi (P,0.0001)
between the FcRc2/2 and GPVI2/2 mice on the pure background
The impact of genetic background on injury induced carotid artery occlusion
was also evaluated in a2b12/2, FcRc2/2, GPVI2/2 and wild type mice on a pure
C57BL/6 genetic background (Figure 4). Time to complete occlusion for the
a2b12/2 mice (70¡7 minutes) was significantly prolonged compared to wild
type animals (52.7¡2.2 minutes), as expected (P50.02). The FcRc2/2 mice

Figure 3. The in vivo thrombotic differences are independent of genetic background. (A) The platelet
count decrement (% change from baseline) following intravenous injection of Type I collagen (25ug) and
epinephrine (1ug) into wild type (WT) (n57), GPVI2/2 (n57), FcRc2/2 (n59) or a2b12/2 (n511) mice on a
pure C57BL/6 background was determined. (B) The number of thrombi observed in the lungs at 3 minutes
after injection of Type I collagen (25ug) and epinephrine (1ug) was determined for wild type (WT), a2b12/2,
GPVI2/2, FcRc2/2 mice on the C57BL/6 background. Thrombi were recorded per mm2 in 6 random 20X
fields.
doi:10.1371/journal.pone.0114035.g003
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Figure 4. Differences in thrombotic occlusion of the carotid artery are independent of genetic
background. The impact of genetic background on photochemically induced endothelial injury on carotid
artery occlusion was also evaluated in a2b12/2, FcRc2/2, GPVI2/2 and wild type mice on a pure C57BL/6
genetic background. The length of time to complete vessel occlusion following photochemical injury was
measured in wild type, a2b12/2, FcRc2/2, and GPVI2/2 mice on the pure genetic background (C57BL/6). The
values represent the mean ¡ SD of WT (n510), a2b12/2 (n510), GPVI2/2 (n55), or FcRc2/2 (n58).
doi:10.1371/journal.pone.0114035.g004

demonstrated an occlusion time of 54.8¡4.8 minutes, similar to wild type
(P50.7). Time to occlusion for the pure GPVI2/2 mice (99¡20 minutes) was
significantly prolonged compared either wild type (P50.006) or FcRc2/2 mice
(P50.02). These data show that mice deficient in the GPVI receptor, but not the
FcRc chain manifest a major defect in carotid artery thrombosis induced by
photochemical injury. Overall, the genetic background did not contribute to the
in vivo variances observed between genotypes in thrombosis.

Platelet adhesion, spreading and aggregation on Type I collagen
are dependent on the a2b1 integrin, the GPVI receptor and the
FcRc receptors
The data presented above describe an unexpected difference in vivo in thrombosis
between mice lacking the GPVI and the FcRc subunits. To better define the
mechanisms for this difference, platelet adhesion using platelets from pure
C57BL/6 animals was evaluated in vitro at 60 minutes (Figure 5A). Wild type
platelets adhered to collagen substrates in a time dependent manner, but not to
BSA (Figure 5A). As previously reported, a2b12/2 platelets failed to adhere.
Although FcRc2/2 and GPVI2/2 platelets adhered to collagen substrates,
adhesion was significantly reduced at 60 minutes compared to adhesion of wild
type platelets. Although reduced compared to wild type, adhesion of FcRc2/2
platelets was significantly greater than adhesion of GPVI2/2 platelets at each time
point (Figure 5B). Expression of the a2b1 integrin was similar on GPVI2/2 and
FcRc2/2 platelets and therefore did not explain the difference in adhesion to
collagen I (data not shown).
The increased adhesion to Type I collagen demonstrated by FcRc2/2 platelets,
compared to GPVI2/2 platelets, suggested one of two possibilities: either the a2b1
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Figure 5. Type I collagen-stimulated platelet adhesion, aggregation, and spreading. (A and B) Purified
platelets isolated from wild type (WT), a2b12/2, GPVI2/2, or FcRc2/2 mice were assayed for adhesion to
Type I collagen (CNI), or BSA for 60 minutes (A) or over a time course of 60 minutes (B) in vitro. Results
represent percentages of adherent platelets (mean of 3 independent experiments performed in triplicate). (C)
Purified platelets isolated from wild type (WT), a2b12/2, GPVI2/2, or FcRc2/2 mice were assayed for
adhesion to Type I collagen (CNI) in the presence or absence of inhibitory anti-a2b12/2 antibody or BSA for
60 minutes in vitro. Results represent percentages of adherent platelets (mean of 2 independent experiments
performed in triplicate). (D) Scanning electron micrographs detail wild type (WT), GPVI2/2, or FcRc2/2 mouse
platelets when adherent to collagen I (CNI) for 60 minutes. Platelets from a2b12/2 mice failed to adhere and
therefore were not observed.
doi:10.1371/journal.pone.0114035.g005
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integrin on FcRc2/2 platelets was expressed in an activated conformation; or, an
alternative collagen binding receptor was mediating adhesion. To differentiate
these two possibilities, the ability of inhibitory anti-a2b1 integrin antibody to
inhibit platelet adhesion was tested. As shown in Figure 5C, the inhibitory antia2b1 integrin antibody completely blocked collagen adhesion by wild type,
FcRc2/2 and GPVI2/2 platelets. Therefore, a2b1 integrin-dependent activation
and collagen adhesion is enhanced in the FcRc2/2 platelets when compared to
GPVI2/2 platelets.
Next we analyzed platelet aggregation. Wild type platelets formed small and
large platelet aggregates during adhesion to collagen I after 60 minutes, but
FcRc2/2 and GPVI2/2 platelets did not (data not shown). There was no
difference in platelet aggregation between the FcRc2/2 and GPVI2/2 platelets.
Correspondingly, wild type and a2b12/2 platelets aggregated in response to
soluble collagen, as measured by turbidometric aggregometry, but neither the
FcRc2/2 nor GPVI2/2 platelets aggregated (data not shown).
We also examined wild type, a2b12/2, GPVI2/2 and FcRc2/2 platelets using
scanning electron microscopy to determine if there were variances in platelet
morphology during adhesion to collagen I (Figure 5D). Individual wild type,
GPVI2/2, and FcRc2/2 formed similar filopodial extensions on collagen I. No
a2b12/2 platelets attached to collagen I and therefore the image was similar to the
BSA negative controls (data not shown).

Protein phospho-tyrosine analyses of wild type, GPVI2/2, and
FcRc2/2 mouse platelets
To determine whether the different phenotypes observed in vivo between wild
type, GPVI2/2, and FcRc2/2 mice were a consequence of alterations in a2b1
integrin-dependent platelet activation signals in response to collagen, we
determined the extent of protein tyrosine phosphorylation following collageninduced platelet activation in vitro (Figure 6A). Mouse platelets from wild type,
GPVI2/2, or FcRc2/2 mice were either untreated or stimulated with 10 mg/mL
collagen I for 1 minute followed by immunoblot analysis of proteins containing
phosphorylated tyrosines. Interestingly, control and collagen-stimulated platelets
from wild type, GPVI2/2, and FcRc2/2 animals showed slightly or moderately
different levels of tyrosine phosphorylation of 72 and 25 kDa proteins,
respectively. These variations in protein tyrosine phosphorylation between
genotypes was quantified for the 72 and 25 kDa proteins in Figure 6A, and the
amounts of phosphorylation correlates with the levels of thrombosis observed in
vivo and with adhesion to collagen substrates in vitro. Wild type platelets
demonstrated a low basal level of phosphorylation of a 72 kDa protein that was
augmented by collagen I stimulation. GPVI2/2 platelets showed the lowest level of
basal and collagen-stimulated tyrosine phosphorylation of the 72 kDa protein.
The FcRc2/2 platelets showed intermediate levels of basal and slight but not
reproducible level of collagen-stimulated tyrosine phosphorylation of the 72 kDa
protein. Both wild type and FcRc2/2 platelets had similar low levels of basal

PLOS ONE | DOI:10.1371/journal.pone.0114035 November 21, 2014

12 / 20

a2b1 Integrin and GPVI/FcRc Receptor in Mouse Models of Thrombosis

Figure 6. Protein phospho-tyrosine analyses of wild type (WT), GPVI2/2, and FcRc2/2 mouse platelets.
(A) Purified platelets from WT, GPVI2/2, or FcRc2/2 mice were either untreated or stimulated with 10 mg/mL
collagen I In the presence of 2 mM MgCl2 for 1 minute followed by immunoblot analysis using antibodies
against phospho-tyrosine (pTyr) or actin. Protein bands of interest are indicated with arrows at molecular
weights of about 25 and 72 kDa. Quantification of the 25 and 72 kDa pTyr bands were performed by
densitometry and normalized to actin. (B) WT, GPVI2/2, or FcRc2/2 mouse platelets stimulated with CNI were
analyzed for phosphorylated Syk (pSyk) and total Syk by immunoblot. In the presence of 2 mM MgCl2, control
platelets or platelets treated with 10 mg/mL CNI for 1 minute, were lysed, and analyzed by Western blot using
antibodies for phospho-Syk (Tyr525/526), total Syk protein, or total phospho-tyrosine. Quantification of the
pSyk and total Syk was performed by densitometry and the value of pSyk normalized to total Syk. (C) Western
blot analysis of WT, GPVI2/2, or FcRc2/2 mouse platelets for phosphorylated RhoGDI and total RhoGDI
following CNI stimulation as described. Quantification of the pRhoGDI and total RhoGDI was performed and
the value of pRhoGDI normalized to total RhoGDI. (D) Western blot analysis of unstimulated WT, GPVI2/2, or
FcRc2/2 mouse platelets for total FcRc protein or actin expression.
doi:10.1371/journal.pone.0114035.g006
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phosphorylation of the 25 kDa protein that were much higher than the levels
observed in GPVI2/2 platelets. Both wild type and FcRc2/2 platelets demonstrated enhanced phosphorylation of the 25 kDa protein with collagen I
stimulation. These data further support an underlying difference between platelet
activities in FcRc2/2 and GPVI2/2 mice.
A potential candidate for the tyrosine-phosphorylated 72 kDa protein is Syk, a
protein tyrosine kinase important in GPVI/FcRc signal transduction and platelet
activation. Therefore, we analyzed Syk phosphorylation at tyrosines 525 and 526,
which are required for Syk activation. Mouse platelets (wild type, GPVI2/2, or
FcRc2/2) were left untreated or stimulated with 10 mg/mL collagen I for 1 minute
followed by immunoblot analysis of phospho-Syk (Tyr525/526) in correlation
with total Syk protein and total protein tyrosine phosphorylation of the 72 kDa
band (Figure 6B). Collagen-treated platelets showed a slightly elevated levels of
phospho-Syk (Tyr525/527) that correlated with total phospho-tyrosine of the
72 kDa protein band when comparing wild type, GPVI2/2, and FcRc2/2
platelets. Wild type had a low basal level of Syk phosphorylation that increased
with collagen I treatment; GPVI2/2 had the lowest level of basal and collagenstimulated Syk phosphorylation; and FcRc2/2 platelets also had low to
intermediate levels of basal and collagen-stimulated Syk phosphorylation as
shown in the quantitation of phospho-Syk (Figure 6B). The difference in
phospho-Syk levels between resting and activated platelets was not significant and
therefore did not contribute to observed phenotype.
Identification of a candidate for the 25 kDa phosphotyrosine protein band was
undertaken, and a potential candidate of this molecular weight was the family of
RhoGDI proteins. RhoGDI has been shown to modulate cellular activities through
regulation of Rho GTPases by inhibiting Rho GTPase activation through a
sequestration mechanism, which is diminished when RhoGDI in tyrosine
phosphorylated (24). We compared baseline and collagen I-induced RhoGDI2
tyrosine phosphorylation in wild type, FcRc2/2, and GPVI2/2 platelets. As shown
in Figures 6C, the 25 kDa phospho-protein band overlays with RhoGDI2.
Significantly enhanced tyrosine phosphorylation of RhoGDI2 in wild type and
FcRc2/2, but not GPVI2/2 platelets occurred in response to Type I collagen.
Since a2b1 integrin-dependent collagen adhesion and RhoGDI2 phosphorylation occurred in FcRc2/2 platelets, but not in GPVI2/2 platelets, the continued
expression of FcRc in GPVI2/2 platelets could be causing a dominant negative
phenotype in the GPVI2/2 mice by interfering with signaling pathways in these
platelets. We therefore determined the expression of FcRc receptor in platelets
from GPVI2/2 mice in comparison to wild type and FcRc2/2 (Figure 6D).
Surprisingly, GPVI2/2 platelets have a similar expression level of FcRc compared
to wild type platelets and not a partial reduction. As expected, no expression was
seen in the FcRc2/2 platelets. The wild type expression levels of FcRc receptor in
GPVI2/2 platelets may cause the varied thrombotic phenotypes observed between
GPVI2/2 and FcRc2/2 mice through increased RhoGDI sequestration of Rho
GTPases and attenuation on actin cytoskeletal dynamics, which are important in
platelet adhesion and thrombosis.
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Discussion
The findings reported in this study demonstrate novel requirements in vivo and in
vitro for the platelet collagen receptors, the a2b1 integrin and the GPVI/FcRc
receptor complex. First, the in vivo data demonstrate by using multiple genetically
modified animals that deletion of the GPVI receptor results in a phenotype that is
distinctly different from that resulting from deletion of the common FcRc chain.
Second, both the a2b1 integrin and the GPVI receptor, but not the FcRc subunit,
influence carotid artery occlusion in vivo. In contrast, the loss of GPVI receptor or
the FcRc chain decreases intravascular thrombosis in response to soluble Type I
collagen, but surprisingly the FcRc2/2 animals retain some thrombotic potential
to collagen. These findings are the first to show disparate effects in thrombosis
between GPVI receptor and FcRc chain knockout mice. Much of our earlier
understanding of the role of the GPVI receptor in collagen-induced platelet
activation and thrombus formation was based on mice lacking the FcRc chain.
The development of the a2b1 integrin-deficient mice (20,21), FcRc-deficient
mice, and GPVI-deficient mice (15), affords an unambiguous opportunity to
address definitively the roles and contributions of these receptors to platelet
activation by collagen in vivo and in vitro. Third, earlier data from a number of
laboratories, including our own, failed to identify a role for the a2b1 integrin in
collagen-induced intravascular thrombosis. We now show that in the absence of
the common FcRc chain the a2b1 integrin promotes a low level of collageninduced platelet activation and thrombosis. Finally, the molecular basis for the
difference in activation status of platelets from FcRc chain-deficient mice and
GPVI-deficient mice correlates to differences in collagen-induced tyrosine
phosphorylation of RhoGDI2.
The identification of different thrombotic responses to collagen observed in
mice with deletion of GPVI or FcRc genes was initially surprising, and it was
logical to assume that this was attributable to the genetic background of mice on a
mixed genetic background. A study by Cheli et al. (25) using the same mixed
GPVI2/2 mice on the 129/SvJ x C57BL/6 background identified a Modifier of
hemostasis (Mh) locus on chromosome 4 that correlated with the extreme but
transient dichotomy in tail bleeding time (tBT) seen in the earlier generations of
these mice. A modest correlation was also observed in the in vivo ferric chlorideinduced carotid artery injury model. With progressive backcrosses to C57BL/6,
this phenotypic difference gradually diminished until later generations of GPVI2/
2
mice that were congenic on the C57BL/6 background exhibit a normal tBT.
Nonetheless, a follow-up study of Mh has identified at least one candidate gene of
interest that is currently under further investigation. Our studies in this report
rule out the possibility that genetic differences arising from the original mixed
background (129/SvJ 6 C57BL/6) are responsible for this unexpected result since
animals with genotypes on pure inbred background (C57BL/6) showed similar
experimental outcomes suggesting that a genetic modifier (such as Mh) was not
responsible for the differences. Thus, we conclude that there is yet another
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mechanism responsible for thrombotic differences between GPVI2/2 or FcRc2/2
mice.
To determine whether differences observed in vivo were demonstrable in
isolated platelets, the ability of FcRc2/2 and GPVI2/2 platelets to respond to
collagen was determined. GPVI2/2 and FcRc2/2 platelets adhered to Type I
collagen substrates, however FcRc2/2 platelets were significantly more adherent
to collagen in an a2b1 integrin-dependent manner than GPVI2/2 platelets. No
differences between GPVI2/2 and FcRc2/2 platelets were seen in in vitro analyses
of aggregation or morphology. Taken together these results suggested that FcRc2/
2
platelets, but not GPVI2/2 platelets, adhered to collagen in an a2b1 integrindependent fashion. During the platelet response to collagen, distinct phosphotyrosine protein profiles were observed between the GPVI2/2 and FcRc2/2
platelets, especially proteins of 72 and 25 kDa. The 25 kDa phosphoprotein was
identified as RhoGDI2, an important regulator of RhoGTPase signaling.
Importantly, tyrosine phosphorylation of RhoGDI inhibits binding to RhoA,
Rac1, and Cdc42 freeing them for activation (26,27). Not much is known about
RhoGDI functions in platelets even though its activity on Cdc42 was revealed in
platelets (28–31). We report that RhoGDI2 phosphorylation is enhanced in
FcRc2/2 platelets when compared to GPVI2/2 platelets upon collagen
stimulation. This suggests that FcRc2/2 platelets may contain a signaling
environment more primed for RhoGTPase activation than GPVI2/2 platelets. In
agreement with our result, Poole et al. observed a slight increase in Syk
phosphorylation in FcRc2/2 platelets with collagen I treatment (32). Mazzucato et
al. showed that platelets lacking GPVI under flow conditions could still adhere to
collagen I and elevate intracellular Ca2+ through a2b1 integrin (33). Awareness of
this difference between GPVI/FcRc knockouts may be pertinent to future research
since a recent study by Boulaftali et al. showed that ITAM containing receptors
(GPVI/FcRc and CLEC2) were critical for a novel form of hemostasis at sites of
inflammation where GPCR signaling was not required (34,35). On the basis of
these results, we propose that GPVI2/2 and FcRc2/2 platelets are poised at
different resting states and GPVI2/2 platelets have a larger activation barrier to
overcome than wild type or FcRc2/2, which explains the differences observed
with the in vivo thrombotic analyses.
Animals deficient in the common FcRc chain, an important signaling subunit
of multiple cell surface receptors, have been extensively evaluated as a model of
GPVI deficiency (32,36). These mice, which lack the GPVI/FcRc receptor, also
lack FceRcI, FccRIII, and FccRI, and are immunodeficient with abnormalities in
macrophage, NK cell, mast cell and B cell function, but fail to manifest a bleeding
diathesis (37). Abnormalities observed with FcRc-deficient platelets in vitro
include defective secretion, platelet activation and aggregation in response to
collagen or GPVI-mimetics. Interestingly, bleeding and platelet function
abnormalities are much less severe in FcRc-null mice than in mice lacking several
of the downstream adaptor/signaling molecules such as SLP76 or PLCc2 (38,39).
These studies initially suggested that other collagen receptors in addition to GPVI/
FcRc also contribute to collagen-induced signals. Work by Konstantinides et al.
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showed that during arterial thrombosis loss of GPVI had variable effects and was
dependent upon wound severity and the presence of activating factors (40). We
now raise the possibility that the platelet response to collagen in mice lacking the
FcRc chain differ in a number of ways from mice lacking only the GPVI subunit.
To exclude the possibility that expression of the FcRc receptor on other cell types
contributes to the phenotype will require additional experiments with plateletselective, FcRc-null animals.
Enhanced adhesion to collagen I and the higher level of protein tyrosine
phosphorylation in collagen-stimulated FcRc2/2 platelets compared to GPVI2/2
platelets suggests FcRc expression in GPVI2/2 platelets mediates a dominantnegative phenotype. The level of FcRc expression remains at wild type levels even
though there is loss of the GPVI/FcRc receptor complex, which suggests that FcRc
could be associating with other interacting proteins in GPVI2/2 platelets and
negatively affecting platelet ITAM signaling pathways through sequestration or
disruption mechanisms. Importantly, in mouse platelets there are no other known
membrane proteins that directly bind FcRc. Dominant negative mutations have
been shown to affect surface receptor function previously (e.g. PDGF and Her2
receptors) (41,42). This inhibitory activity is not present upon loss of FcRc
expression or correct partnering of FcRc proteins. We speculate that the decreased
levels of tyrosine phosphorylated proteins (RhoGDI) in collagen-stimulated
GPVI2/2 platelets attenuates platelet activities like cytoskeletal rearrangement,
priming of a2b1 integrin, or synergy with GPCR signaling, which are important
processes of inactivation of wild type platelets (22,43,44). Interestingly, the loss of
a2b1 integrin on FcRc2/2 platelets decreased collagen-stimulated aggregation in
vivo and suggests a2b1 signaling is negatively regulated by inappropriate
expression of FcRc in GPVI2/2 platelets.
In summary, we identify in vivo and in vitro differences in thrombosis between
a2b12/2, GPVI2/2 and FcRc2/2 platelets, which surprisingly revealed variances
between GPVI2/2 and FcRc2/2 platelets. This variation in phenotype seems to be
attributable to normal expression levels of FcRc in GPVI2/2 platelets and
produces a dominant negative effect through a decrease in protein tyrosine
phosphorylation of RhoGDI leading to increased inhibition of RhoGTPases. In
addition, these findings suggest a complex signaling network downstream of the
platelet collagen receptors. Shida and colleagues recently published a comprehensive analysis of von Willebrand factor and its interactions with collagen in
conjunction with GPVI and the a2b1 integrin during thrombosis and showed
major but overlapping functions (45). Further understanding of the functions of
GPVI/FcRc on platelets and the involvement of RhoGDI and other molecules,
including von Willebrand factor in this complex pathway is necessary and
important as these receptors are potential targets for antithrombotic therapy.
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